How To Be Prepared For A Catastrophic Data Breach
Executive Summary
Pharmaceutical companies will be directly affected by the EU’s General Data Protection Regulation because they often hold large amounts of personal health information, such as clinical trial data, and any accidental disclosure of those data will be taken very seriously by the regulatory authorities. Richard Dickinson, Jacqueline Mulryne and Zoe Walkinshaw look at what companies should be doing to limit the impact of a catastrophic data breach on their corporate reputation, the individuals affected, and the validity of the data.
You may also be interested in...
How To Deal With A Dawn Raid By Competition Authorities
Pharmaceutical firms in Europe are increasingly the target of dawn raids by enforcement authorities in search of evidence of anti-competitive behavior. As John Schmidt and Will Mudge explain, such raids can be highly disruptive and distressing, and companies need to ensure they have robust processes and training in place so that staff can respond appropriately if government agents arrive at their offices unannounced.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.